SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
Ryan Allway November 24th, 2021 Psychedelics Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on... Read more
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind’s Proprietary MEAI Compound
Ryan Allway November 18th, 2021 Psychedelics Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project Toronto, Ontario–(Newsfile Corp. – November 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived... Read more
Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
Ryan Allway October 26th, 2021 Psychedelics Output will be used to advance clinical testing of MEAI as a treatment for Alcohol Use Disorder and Binge Drinking TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )